Marcus Mize
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Marcus Mize has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Carrie Baker
Cape Fear Valley Medical Center, Fayetteville, NC, USA
3 shared publications - Riley D. Bowers
Department of Pharmacy Practice, Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC, USA
3 shared publications - Katlyn Womble
Pharmacy, Cape Fear Valley Medical Center
1 shared publication
Latest Publications
- 26 October 2026
- Published by SAGE Publications in Journal of Pharmacy Practice
Dose-Reduced Apixaban for Thromboembolism in a Patient With Obesity on Cobicistat: A Case Report
Background/Objective: Current guidelines recommend a 50% dose reduction of apixaban for patients receiving strong CYP3A4/P-glycoprotein (P-gp) inhibitors regardless of body habitus. However, evidence supporting this dose adjustment in patients with severe obesity (BMI >40 kg/m 2 ) is limited. This report describes the use of dose-reduced apixaban for the treatment of venous thromboembolism in a patient with a BMI >50 kg/m 2 receiving a strong CYP3A4/P-gp inhibitor. Summary: A 38-year-old female with a BMI of 81.71 kg/m 2 and a history of HIV on a cobicistat-containing antiretroviral regimen was diagnosed with a left femoral deep vein thromboembolism. She was initially treated with warfarin and enoxaparin bridge therapy but was transitioned to apixaban prior to discharge. Apixaban was initiated at a 50% dose reduction due to the concomitant use of cobicistat, a strong CYP3A4/P-gp inhibitor. The patient successfully completed therapy without recurrence of thromboembolism or bleeding complications. Conclusion: This case demonstrates the successful use of dose-reduced apixaban in a patient with a BMI >50 kg/m 2 receiving a CYP3A4/P-gp inhibitor for the treatment of venous thromboembolism and adds to available literature on apixaban dosing in patients with obesity.
- 26 October 2026
- Published by SAGE Publications in Journal of Pharmacy Practice
Dose-Reduced Apixaban for Thromboembolism in a Patient With Obesity on Cobicistat: A Case Report
Background/Objective: Current guidelines recommend a 50% dose reduction of apixaban for patients receiving strong CYP3A4/P-glycoprotein (P-gp) inhibitors regardless of body habitus. However, evidence supporting this dose adjustment in patients with severe obesity (BMI >40 kg/m 2 ) is limited. This report describes the use of dose-reduced apixaban for the treatment of venous thromboembolism in a patient with a BMI >50 kg/m 2 receiving a strong CYP3A4/P-gp inhibitor. Summary: A 38-year-old female with a BMI of 81.71 kg/m 2 and a history of HIV on a cobicistat-containing antiretroviral regimen was diagnosed with a left femoral deep vein thromboembolism. She was initially treated with warfarin and enoxaparin bridge therapy but was transitioned to apixaban prior to discharge. Apixaban was initiated at a 50% dose reduction due to the concomitant use of cobicistat, a strong CYP3A4/P-gp inhibitor. The patient successfully completed therapy without recurrence of thromboembolism or bleeding complications. Conclusion: This case demonstrates the successful use of dose-reduced apixaban in a patient with a BMI >50 kg/m 2 receiving a CYP3A4/P-gp inhibitor for the treatment of venous thromboembolism and adds to available literature on apixaban dosing in patients with obesity.
- 21 August 2026
- Published by SAGE Publications in Journal of Pharmacy Practice
Factors Influencing Post-Residency Career Choices Among Graduating PGY1 Pharmacy Residents
Purpose: To examine factors that influence the post-residency decision-making process of PGY1 pharmacy residents. Methods: An eleven-question survey was disseminated to individuals who completed a PGY1 residency in the past 5 years (2019-2023). The primary outcome was the most common factors that influenced PGY1 residents to choose either a PGY2 residency or employment after graduation. Factors evaluated included finances, family obligations, clinical experience, burnout, and career opportunities. Only fully completed surveys were included in analyses. Results: A total of 135 participants completed the survey. Response rate from all possible PGY1 graduates was 1.3%, with a response rate of 50.6% of those who clicked the distributed survey link. Of the 135 responses, 89 (66%) pursued PGY2 residency, while 46 (34%) pursued employment. Of those pursuing PGY2, desire to specialize, clinical experience, and career opportunities were the top 3 factors influencing their decision. Those choosing employment reported well-being/burnout, career opportunities, and job outlook as their top 3 most influential factors. Statistically significant differences were observed regarding the influence of 7 (64%) factors contributing to deciding between pursuing a PGY2 residency or employment, although some, including convenience and competitiveness of a specialty, had low scores on overall influence. Conclusion: Many factors influence post-PGY1 career decision with desire to specialize being the most influential factor among those pursuing PGY2, while well-being/burnout was the most influential factor among those pursuing employment. By identifying these factors, the study contributes to a deeper understanding of resident preferences and informs strategies to optimize pharmacy education and training programs.
- 21 August 2026
- Published by SAGE Publications in Journal of Pharmacy Practice
Factors Influencing Post-Residency Career Choices Among Graduating PGY1 Pharmacy Residents
Purpose: To examine factors that influence the post-residency decision-making process of PGY1 pharmacy residents. Methods: An eleven-question survey was disseminated to individuals who completed a PGY1 residency in the past 5 years (2019-2023). The primary outcome was the most common factors that influenced PGY1 residents to choose either a PGY2 residency or employment after graduation. Factors evaluated included finances, family obligations, clinical experience, burnout, and career opportunities. Only fully completed surveys were included in analyses. Results: A total of 135 participants completed the survey. Response rate from all possible PGY1 graduates was 1.3%, with a response rate of 50.6% of those who clicked the distributed survey link. Of the 135 responses, 89 (66%) pursued PGY2 residency, while 46 (34%) pursued employment. Of those pursuing PGY2, desire to specialize, clinical experience, and career opportunities were the top 3 factors influencing their decision. Those choosing employment reported well-being/burnout, career opportunities, and job outlook as their top 3 most influential factors. Statistically significant differences were observed regarding the influence of 7 (64%) factors contributing to deciding between pursuing a PGY2 residency or employment, although some, including convenience and competitiveness of a specialty, had low scores on overall influence. Conclusion: Many factors influence post-PGY1 career decision with desire to specialize being the most influential factor among those pursuing PGY2, while well-being/burnout was the most influential factor among those pursuing employment. By identifying these factors, the study contributes to a deeper understanding of resident preferences and informs strategies to optimize pharmacy education and training programs.
- 19 September 2024
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 38 (2) , 270-274
Very High Warfarin Dosing Requirements in a Patient With Tuberculosis and a Pulmonary Embolism: A Case Report
Purpose: To describe a case of significantly increased warfarin requirements in a patient receiving rifampin for the management of tuberculosis. Summary: A 76-year-old male was admitted due to altered mentation, cough, and weight loss. He was diagnosed concurrently with tuberculosis and a pulmonary embolism. Given the profound effect of rifampin on CYP450 enzymes, direct oral anticoagulants were avoided and warfarin therapy was selected. Management was further complicated by a gastrointestinal bleed during admission, history of cancer, and low body weight. After several weeks of daily international normalized ratio monitoring, a stable regimen of 14 mg of warfarin daily was established, allowing for the patient’s safe discharge. Practice Implications: This report underscores the significance of tailored treatment plans, vigilant monitoring, and interdisciplinary collaboration which are necessary to navigate the complexities associated with these medications and optimize patient outcomes.
- 19 September 2024
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 38 (2) , 270-274
Very High Warfarin Dosing Requirements in a Patient With Tuberculosis and a Pulmonary Embolism: A Case Report
Purpose: To describe a case of significantly increased warfarin requirements in a patient receiving rifampin for the management of tuberculosis. Summary: A 76-year-old male was admitted due to altered mentation, cough, and weight loss. He was diagnosed concurrently with tuberculosis and a pulmonary embolism. Given the profound effect of rifampin on CYP450 enzymes, direct oral anticoagulants were avoided and warfarin therapy was selected. Management was further complicated by a gastrointestinal bleed during admission, history of cancer, and low body weight. After several weeks of daily international normalized ratio monitoring, a stable regimen of 14 mg of warfarin daily was established, allowing for the patient’s safe discharge. Practice Implications: This report underscores the significance of tailored treatment plans, vigilant monitoring, and interdisciplinary collaboration which are necessary to navigate the complexities associated with these medications and optimize patient outcomes.